Pharmaceutical Economics & Health PolicyManagement of NSAID-induced gastropathy: an economic decision analysis
References (45)
- et al.
Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States 1866–1990
J Clin Epidemiol
(1992) - et al.
Current issues in NSAID therapy
Prim Care
(1990) Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: Prophylactic and therapeutic strategies
Am J Med
(1994)- et al.
Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs
Am J Med
(1988) - et al.
Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double-blind, placebo-controlled trial
Lancet
(1988) - et al.
Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models
Am J Med
(1991) - et al.
A review of selected newer nonsteroidal anti-inflammatory drugs
Am Fam Phys
(1994) Nonsteroidal anti-inflammatory drugs and the gut
South Med J
(1996)- et al.
Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study
Dig Dis Sci
(1995) - et al.
Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons
Am J Epidemiol
(1995)
Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study
Arch Intern Med
Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury
Am J Med
FDA's NSAID class labeling estimate of 4–6% GI adverse reaction annually is not valid, PMA maintains: PMA proposes industry-consensus NSAID label warning
FDA Reports
Toward an understanding of NSAID-related adverse events: The contribution of longitudinal data
Scand J Rheumatol
NSAID-associated gastrointestinal damage and the elderly
Pract Gastroenterol
Assessing and understanding patient risk
Scand J Rheumatol
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs
Ann Intern Med
Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients
Am J Gastroenterol
Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: A prospective, double-blind, multicenter study
Am J Gastroenterol
Drug Utilization Evaluation of Michigan Medicaid claims database (12/1/94–11/30/95)
Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials
Arch Intern Med
Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine
BMJ
Cited by (21)
Cost-effectiveness of Low-dose Submicron Diclofenac Compared With Generic Diclofenac
2016, Clinical TherapeuticsCitation Excerpt :In our study, we used the diclofenac dose–toxicity relationship estimated by Odom et al19 as key input for a decision-analytic model, which we developed to estimate the economic and health benefits of submicron diclofenac in reducing AEs, assuming pain relief similar to that with generic diclofenac, from a US payer’s perspective. Prior to formulating the model, we reviewed economic models presented in health technology assessment reports by the UK National Institute for Health and Care Excellence21–23 as well as published economic models that analyzed the cost-effectiveness of various NSAID-prescribing strategies that might reduce the occurrence of NSAID-induced AEs.24–32 These decision-analytic models included GI-related AEs such as GI discomfort or dyspepsia; symptomatic ulcer; serious peptic ulcer complication that leads to hospital admission; serious GI event or complication that requires a hospitalization; serious GI event or complication that leads to death, obstruction, bleeding, and/or ulcer; and peptic ulcer bleeding.
Gastrointestinal toxicity associated with nonsteroidal anti-inflammatory drugs: Epidemiologic and economic issues
2001, Gastroenterology Clinics of North AmericaCitation Excerpt :Despite the availability of some newer NSAIDs as well as gastroprotective drugs, the iatrogenic cost factor may not have decreased over 15 years. Numerous economic analyses of the cost-effectiveness of misoprostol to prevent the serious gastrointestinal complications of NSAIDs have been performed.7,15,18,20,27,35,51,54,67 Gabriel and Wagner28 summarized the challenges in interpreting this literature: There was significant variation across virtually all methodologic parameters, making it problematic to compare the results of different studies.
Diagnosis and treatment of nonsteroidal anti-inflammatory drug associated upper gastrointestinal toxicity
2000, Gastroenterology Clinics of North AmericaCitation Excerpt :NSAID users take acid-suppressive therapy twice as often as nonusers.62 Of NSAID users, 22% take either H2-receptor antagonists or proton-pump inhibitors.54 Some studies have shown that H2-receptor antagonists accelerate the healing78,93 or prevent the occurrence of duodenal ulcers,93,154 especially if NSAID use is discontinued.